PLUN Stock Overview
A medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ProstaLund AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.48 |
| 52 Week High | SEK 3.04 |
| 52 Week Low | SEK 0.40 |
| Beta | 0.71 |
| 11 Month Change | -3.23% |
| 3 Month Change | -57.23% |
| 1 Year Change | -80.21% |
| 33 Year Change | -91.45% |
| 5 Year Change | -66.50% |
| Change since IPO | -97.01% |
Recent News & Updates
Shareholder Returns
| PLUN | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -2.4% | -4.0% | -4.3% |
| 1Y | -80.2% | -0.002% | 12.6% |
Return vs Industry: PLUN underperformed the Swedish Medical Equipment industry which returned -0% over the past year.
Return vs Market: PLUN underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
| PLUN volatility | |
|---|---|
| PLUN Average Weekly Movement | 15.6% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: PLUN's share price has been volatile over the past 3 months.
Volatility Over Time: PLUN's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 6 | Johan Wennerholm | prostalund.se |
ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally. It offers CoreTherm, a heat treatment for benign prostate enlargement; CoreFlow soft stent; Oruflow, a urine flow meter; Dosi-Fuser, a disposable continuous infusion system; and Dosi-Flow, a gravitation unit with a flow regulator for dosing of medicines. The company also provides Schelin Catheter, an injection tool that allows the urologists to administer drugs into the prostate in a sterile way through the urethra.
ProstaLund AB (publ) Fundamentals Summary
| PLUN fundamental statistics | |
|---|---|
| Market cap | SEK 58.94m |
| Earnings (TTM) | -SEK 18.58m |
| Revenue (TTM) | SEK 20.19m |
2.9x
P/S Ratio-3.2x
P/E RatioIs PLUN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLUN income statement (TTM) | |
|---|---|
| Revenue | SEK 20.19m |
| Cost of Revenue | SEK 6.11m |
| Gross Profit | SEK 14.08m |
| Other Expenses | SEK 32.66m |
| Earnings | -SEK 18.58m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 19, 2024
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 69.74% |
| Net Profit Margin | -92.06% |
| Debt/Equity Ratio | 2.6% |
How did PLUN perform over the long term?
See historical performance and comparison